578 reports of this reaction
1.6% of all KETOPROFEN reports
#20 most reported adverse reaction
HEPATIC ENZYME INCREASED is the #20 most commonly reported adverse reaction for KETOPROFEN, manufactured by Allegis Pharmaceuticals, Inc.. There are 578 FDA adverse event reports linking KETOPROFEN to HEPATIC ENZYME INCREASED. This represents approximately 1.6% of all 36,564 adverse event reports for this drug.
Patients taking KETOPROFEN who experience hepatic enzyme increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC ENZYME INCREASED is a less commonly reported adverse event for KETOPROFEN, but still significant enough to appear in the safety profile.
In addition to hepatic enzyme increased, the following adverse reactions have been reported for KETOPROFEN:
The following drugs have also been linked to hepatic enzyme increased in FDA adverse event reports:
HEPATIC ENZYME INCREASED has been reported as an adverse event in 578 FDA reports for KETOPROFEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC ENZYME INCREASED accounts for approximately 1.6% of all adverse event reports for KETOPROFEN, making it a notable side effect.
If you experience hepatic enzyme increased while taking KETOPROFEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.